By  | February 26, 2013 |  1
I clipped sentences while reading the last few weeks with the intent of compiling them for this post.  I want you to examine below and glean a pattern.
By  | February 26, 2013 |  23
I’m well aware that a good fraction of the people in this country – let’s call them Rush fans – spend their lives furious at the New York Times. I am not one of them. I love the Grey Lady; it would be high on my list of things to bring to a desert island. […]
By  | February 24, 2013 |  0
This large placebo controlled trial of patients with VTE, already treated with 3 months of anticoagulation, randomized them to dabigatran, warfarin, or placebo; dabigatran and warfarin had similar rates of recurrent VTE, but dabigatran had lower rates of major/minor bleeding (abstract).
By  | February 24, 2013 |  0
The Surviving Sepsis Campaign guidelines have been updated. Some of the highlights include (abstract): Initial fluids with crystalloids at 30cc/kg, with goal in first 6 hours of CVP 8-12mmHg, MAP>65 mmHg, and urine output >0.5cc/kg/hr; Antibiotics within 1 hour No steroids unless refractory shock and no RBC transfusions unless Hb<7 Vasopressor of choice is norepinephrine […]
By  | February 24, 2013 |  0
This large meta-analysis found a significant mortality benefit for all beta blockers in patients with systolic CHF, with no significant differences between the different types, indicating any beta blocker will do (abstract).
By  | February 24, 2013 |  0
This small retrospective single center cohort found that 22% of patients on combination fluoroquinolone-azole drugs had clinically significant prolongation of their QT interval. Careful monitoring should be done for patients on this combination of drugs (abstract).